GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised stock options to acquire 10,000 shares of common stock at $38.68 per share, then sold 10,000 shares in open-market transactions at $140.00 per share.
Following these transactions, he directly owns 43,681 shares of common stock, which includes 5,230 restricted stock units that have not yet vested or been delivered. Both the sales and the option exercises were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating the activity was scheduled in advance.
GLAUKOS Corp executive Joseph E. Gilliam, the company’s President and COO, reported an open-market sale of 19,573 shares of common stock at a price of $143.54 per share.
After this transaction, he directly held 73,419 shares, which includes 43,925 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp director Leana Wen reported an open-market sale of 1,700 shares of common stock at $143.35 per share. After this transaction, she directly holds 19,739 shares, which the filing states includes 2,731 restricted stock units that are unvested or with deferred delivery.
Glaukos Corporation is sharing an investor presentation that outlines its growth strategy, diversified ophthalmic pipeline and recent financial performance. The company highlights 12 commercialized products and 13 disclosed pipeline programs across glaucoma, keratoconus, blepharitis, myopia and retinal disease.
Net sales grew from $283 million in 2022 to $507 million in 2025, supported by innovations such as iStent, iDose TR and keratoconus therapies Photrexa and Epioxa. The presentation cites 30% 2025 topline growth, a 20% 10‑year revenue CAGR and roughly $800 million invested in R&D since 2018.
For 1Q 2026, Glaukos reports an adjusted gross margin of 84% and cash and equivalents of $281 million with no debt as of March 31, 2026. Sales guidance for 2026 has a midpoint of $627.5 million, underscoring expectations for continued expansion supported by global infrastructure in 17 countries and more than 300 commercial personnel.
Fidelity Brokerage Services LLC submitted a Form 144 notifying an intent to sell 19,573 shares of Common Stock of GKOS as reported on 05/01/2026. The shares arise from multiple restricted stock vesting events dated 12/13/2024 through 04/01/2025, with individual vesting amounts listed in the filing.
Glaukos Corp. notice of proposed resale of 10,000 shares of Common Stock by Fidelity Brokerage Services LLC under Rule 144. The filing lists recent open‑market dispositions by Alex R. Thurman totaling 4,657 shares across March 17, 24 and 25, 2026, with cash proceeds reported for each trade.
Glaukos Corporation reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $150.6 million from $106.7 million a year earlier, driven mainly by higher U.S. glaucoma revenue from the iDose TR sustained-release implant and growth in international glaucoma procedures.
Corneal health revenue also increased as Photrexa and the early Epioxa launch contributed more U.S. sales. Gross margin was 78%, similar to last year, but higher selling, general and administrative expenses of $92.9 million and research and development spending of $44.1 million kept the company in the red, with a net loss of $19.8 million, or $0.34 per share.
Glaukos ended the quarter with $280.5 million in cash, cash equivalents, short-term investments and restricted cash. The company highlighted an option agreement for potential new drug technology and noted a permanent HCPCS J-code for Epioxa effective July 2026, which is expected to simplify U.S. reimbursement for its new keratoconus therapy.
Glaukos Corp reported that Vanguard Capital Management beneficially owns 2,947,047 shares of Common Stock, representing 5.07% of the class. The filing states Vanguard has sole dispositive power over 2,947,047 shares and sole voting power for 438,276 shares.
The Schedule 13G notes these holdings include securities held for Vanguard funds and managed accounts; the filing is signed by Vanguard's Head of Global Fund Administration.